(By – Emily Bazar, Kaiser Health News)
Perhaps nothing triggers frustration and hope in patients like prescription drugs.
Consider the hepatitis C drug Sovaldi, infamous for its $84,000 retail price tag for a 12-week course.
Despite the price, the drug embodies significant hope. It, and other recently approved hepatitis C medications, have vastly improved treatment of the disease.
Sovaldi’s potential was confirmed during clinical trials when it was tested on humans as part of the drug approval process. Many hepatitis B patients probably wish they could have participated. Read more…
Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.